Cardioprotective Potential of Iron Chelators and Prochelators
Authors:
- 14 March 2019
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 26 (2) , 288-301
Abstract
Heart is a particularly sensitive organ to iron overload and cardiomyopathy due to the excessive cardiac iron deposition causes most deaths in disorders such as beta-thalassemia major. Free or loosely bound iron ions readily cycle between ferrous and ferric states and catalyze Haber-Weiss reaction that yields highly reactive and toxic hydroxyl radicals. Treatment with iron chelators (desferrioxamine, deferiprone, and deferasirox) substantially improved cardiovascular morbidity and mortality in iron overloaded patients. Furthermore, iron chelators have been studied in various cardiovascular disorders with known or presumed oxidative stress roles (e.g., ischemia/reperfusion injury) also in patients with normal body iron contents. The pharmacodynamic and pharmacokinetic properties of these chelators are critical for effective therapy. For example, the widely clinically used but hydrophilic chelator desferrioxamine suffers from poor plasma membrane permeability, which means that high and clinically unachievable concentrations/doses must be employed to obtain cardioprotection. Therefore, small-molecular and lipophilic chelators with oral availability are more suitable for this purpose, particularly in states without systemic iron overload. Apart from agents that are already used in clinical practice, aroylhydrazone iron chelators, namely salicylaldehyde isonicotinoyl hydrazone (SIH), have provided promising results. However, the use of classical iron-chelating agents is associated with a risk of toxicity due to indiscriminate iron depletion. Recent studies have therefore focused on "masked" prochelators that have little or no affinity for iron until site-specific activation by reactive oxygen species.Keywords
Funding Information
- Czech Science Foundation (13-15008S)
This publication has 131 references indexed in Scilit:
- Catalytic Inhibitors of Topoisomerase II Differently Modulate the Toxicity of Anthracyclines in Cardiac and Cancer CellsPLOS ONE, 2013
- Iron Overload Cardiomyopathy in Clinical PracticeCirculation, 2011
- Iron chelation with salicylaldehyde isonicotinoyl hydrazone protects against catecholamine autoxidation and cardiotoxicityFree Radical Biology and Medicine, 2011
- Ischemia/reperfusion injury and cardioprotective mechanisms: Role of mitochondria and reactive oxygen speciesWorld Journal of Cardiology, 2011
- Iron prochelator BSIH protects retinal pigment epithelial cells against cell death induced by hydrogen peroxideJournal of Inorganic Biochemistry, 2008
- Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazoneBritish Journal of Pharmacology, 2008
- The MCK mouse heart model of Friedreich's ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelationProceedings of the National Academy of Sciences, 2008
- A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeuticsProceedings of the National Academy of Sciences, 2006
- The role of reactive oxygen and nitrogen species in cellular iron metabolismFree Radical Research, 2006
- Iron chelators of the pyridoxal isonicotinoyl hydrazone classBioMetals, 1989